Huang Peng, Zhang Jiahui, Duan Wenqian, Jiao Juying, Leng Aijing, Qu Jialin
Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Department of Respiratory Medicine, Suixian People's Hospital of Henan, Shangqiu, China.
Front Pharmacol. 2022 Oct 20;13:982893. doi: 10.3389/fphar.2022.982893. eCollection 2022.
When coronavirus disease 2019 (COVID-19) develops into the severe phase, lung injury, acute respiratory distress syndrome, and/or respiratory failure could develop within a few days. As a result of pulmonary tissue injury, pathomorphological changes usually present endothelial dysfunction, inflammatory cell infiltration of the lung interstitium, defective gas exchange, and wall leakage. Consequently, COVID-19 may progress to tremendous lung injury, ongoing lung failure, and death. Exploring the treatment drugs has important implications. Recently, the application of traditional Chinese medicine had better performance in reducing fatalities, relieving symptoms, and curtailing hospitalization. Through constant research and study, plant polysaccharides may emerge as a crucial resource against lung injury with high potency and low side effects. However, the absence of a comprehensive understanding of lung-protective mechanisms impedes further investigation of polysaccharides. In the present article, a comprehensive review of research into plant polysaccharides in the past 5 years was performed. In total, 30 types of polysaccharides from 19 kinds of plants have shown lung-protective effects through the pathological processes of inflammation, oxidative stress, apoptosis, autophagy, epithelial-mesenchymal transition, and immunomodulation by mediating mucin and aquaporins, macrophage, endoplasmic reticulum stress, neutrophil, TGF-β1 pathways, Nrf2 pathway, and other mechanisms. Moreover, the deficiencies of the current studies and the future research direction are also tentatively discussed. This research provides a comprehensive perspective for better understanding the mechanism and development of polysaccharides against lung injury for the treatment of COVID-19.
当2019冠状病毒病(COVID-19)发展到重症阶段时,可能在数天内出现肺损伤、急性呼吸窘迫综合征和/或呼吸衰竭。由于肺组织损伤,病理形态学变化通常表现为内皮功能障碍、肺间质炎症细胞浸润、气体交换缺陷和管壁渗漏。因此,COVID-19可能进展为严重的肺损伤、持续的肺衰竭和死亡。探索治疗药物具有重要意义。最近,中药的应用在降低死亡率、缓解症状和缩短住院时间方面表现更好。通过不断的研究,植物多糖可能成为一种高效低毒的抗肺损伤关键资源。然而,对其肺保护机制缺乏全面了解阻碍了对多糖的进一步研究。在本文中,对过去5年植物多糖的研究进行了全面综述。共有来自19种植物的30种多糖通过炎症、氧化应激、细胞凋亡、自噬、上皮-间质转化和免疫调节等病理过程,通过介导粘蛋白和水通道蛋白、巨噬细胞、内质网应激、中性粒细胞、TGF-β1通路、Nrf2通路等机制显示出肺保护作用。此外,还初步讨论了当前研究的不足和未来的研究方向。本研究为更好地理解多糖抗肺损伤治疗COVID-19的机制和开发提供了全面的视角。